Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases

Series A financing co-led by Westlake Village BioPartners and Versant Ventures Company advancing systemically delivered, skeletal and cardiac muscle targeted, liver de-targeted capsid and cargo technology platforms Initial pipeline addressing myotoni... Regenerative Medicine, Venture Capital Kate Therapeutics, gene therapy, X-linked myotubular myopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news